Vitiello A, Sette A, Yuan L, Farness P, Southwood S, Sidney J, Chesnut R W, Grey H M, Livingston B
R.W. Johnson Pharmaceutical Research Institute, San Diego, CA 92121, USA.
Eur J Immunol. 1997 Mar;27(3):671-8. doi: 10.1002/eji.1830270315.
To study the mechanisms that influence the immunogenicity and immunodominance of potential cytotoxic T lymphocyte (CTL) epitopes, we conducted a systematic analysis of the CTL response raised in HLA-A0201/Kb (A2/Kb) transgenic mice against the viral antigen, hepatitis B virus polymerase (HBV pol). From a pool of 26 nonamer peptides containing the HLA-A0201-binding motif, we selected A2-binding peptides, immunized A2/Kb animals, and tested the CTL raised against the peptide for recognition of HBV pol transfectants. Of nine immunogenic CTL epitopes, only four were recognized on HBV pol transfectants, whereas the other five were cryptic. Characterization of the peptide-specific CTL lines indicated that crypticity may result from either poor processing or low T cell receptor (TCR) avidity. To identify the immunodominant epitopes, we determined the CTL specificities induced in A2/Kb animals in response to priming with HBV pol cDNA. We obtained a response against three epitopes that were contained with the set of four epitopes recognized by peptide-specific CTL on HBV pol transfectants. Comparative analysis of cDNA priming and peptide priming revealed, therefore, the presence of a subdominant epitope. We conclude that for the HBV pol antigen, the repertoire of CTL specificities is shaped by major histocompatibility complex class I peptide binding capacity, antigen processing, and TCR availability.
为了研究影响潜在细胞毒性T淋巴细胞(CTL)表位免疫原性和免疫显性的机制,我们对HLA-A0201/Kb(A2/Kb)转基因小鼠针对病毒抗原乙型肝炎病毒聚合酶(HBV pol)产生的CTL反应进行了系统分析。从包含HLA-A0201结合基序的26个九肽库中,我们选择了A2结合肽,免疫A2/Kb动物,并检测针对该肽产生的CTL对HBV pol转染细胞的识别能力。在九个免疫原性CTL表位中,只有四个在HBV pol转染细胞上被识别,而其他五个是隐蔽性的。肽特异性CTL系的特征表明,隐蔽性可能是由于加工不良或T细胞受体(TCR)亲和力低所致。为了鉴定免疫显性表位,我们确定了A2/Kb动物在经HBV pol cDNA启动后诱导的CTL特异性。我们获得了针对三个表位的反应,这三个表位包含在肽特异性CTL在HBV pol转染细胞上识别的四个表位组中。因此,对cDNA启动和肽启动的比较分析揭示了一个亚显性表位的存在。我们得出结论,对于HBV pol抗原,CTL特异性库是由主要组织相容性复合体I类肽结合能力、抗原加工和TCR可用性决定的。